Cell Reports (Jul 2021)
Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19
- Yu Kaku,
- Takeo Kuwata,
- Hasan Md Zahid,
- Takao Hashiguchi,
- Takeshi Noda,
- Noriko Kuramoto,
- Shashwata Biswas,
- Kaho Matsumoto,
- Mikiko Shimizu,
- Yoko Kawanami,
- Kazuya Shimura,
- Chiho Onishi,
- Yukiko Muramoto,
- Tateki Suzuki,
- Jiei Sasaki,
- Yoji Nagasaki,
- Rumi Minami,
- Chihiro Motozono,
- Mako Toyoda,
- Hiroshi Takahashi,
- Hiroto Kishi,
- Kazuhiko Fujii,
- Tsuneyuki Tatsuke,
- Terumasa Ikeda,
- Yosuke Maeda,
- Takamasa Ueno,
- Yoshio Koyanagi,
- Hajime Iwagoe,
- Shuzo Matsushita
Affiliations
- Yu Kaku
- Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan
- Takeo Kuwata
- Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan; Corresponding author
- Hasan Md Zahid
- Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan
- Takao Hashiguchi
- Labolatory of Medical Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan; Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan
- Takeshi Noda
- Laboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan; CREST, Japan Science and Technology Agency, Kawaguchi, Japan
- Noriko Kuramoto
- Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan
- Shashwata Biswas
- Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan
- Kaho Matsumoto
- Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan
- Mikiko Shimizu
- Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan
- Yoko Kawanami
- Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan
- Kazuya Shimura
- Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan
- Chiho Onishi
- Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan
- Yukiko Muramoto
- Laboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan
- Tateki Suzuki
- Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan
- Jiei Sasaki
- Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan
- Yoji Nagasaki
- Division of Infectious Diseases, Clinical Research Institute, National Hospitalization Organization, Kyushu Medical Center, Fukuoka, Japan
- Rumi Minami
- Internal Medicine, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan
- Chihiro Motozono
- Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan
- Mako Toyoda
- Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan
- Hiroshi Takahashi
- Department of Respiratory Medicine, Kumamoto City Hospital, Kumamoto 862-8505, Japan
- Hiroto Kishi
- Department of Respiratory Medicine, Kumamoto City Hospital, Kumamoto 862-8505, Japan
- Kazuhiko Fujii
- Department of Respiratory Medicine, Kumamoto City Hospital, Kumamoto 862-8505, Japan
- Tsuneyuki Tatsuke
- Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
- Terumasa Ikeda
- Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan
- Yosuke Maeda
- Department of Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan
- Takamasa Ueno
- Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan
- Yoshio Koyanagi
- Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan
- Hajime Iwagoe
- Department of Infectious Disease, Kumamoto City Hospital, Kumamoto 862-8505, Japan
- Shuzo Matsushita
- Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan; Corresponding author
- Journal volume & issue
-
Vol. 36,
no. 2
p. 109385
Abstract
Summary: Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, SARS-CoV-2 variants with mutations in the spike protein have emerged in many countries. To evaluate the efficacy of neutralizing antibodies induced in convalescent patients against emerging variants, we isolate anti-spike mAbs from two convalescent COVID-19 patients infected with prototypic SARS-CoV-2 by single-cell sorting of immunoglobulin-G-positive (IgG+) memory B cells. Anti-spike antibody induction is robust in these patients, and five mAbs have potent neutralizing activities. The efficacy of most neutralizing mAbs and convalescent plasma samples is maintained against B.1.1.7 and mink cluster 5 variants but is significantly decreased against variants B.1.351 from South Africa and P.1 from Brazil. However, mAbs with a high affinity for the receptor-binding domain remain effective against these neutralization-resistant variants. Rapid spread of these variants significantly impacts antibody-based therapies and vaccine strategies against SARS-CoV-2.
